A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer

Phase 2 Unknown 30 enrolled Maxinovel Pty., Ltd.

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a single-arm, multi-center phase II clinical study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With advanced gastric cancer or gastroesophageal junction cancer.

Timeline

Start: 2022-06
Primary completion: 2022-12
Completion: 2023-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MAX-40279	Unknown	50 mg	Oral
Subject	MAX-40279	Unknown	70 mg	Oral

A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer

Summary

Timeline

Drugs

Indications